Aaron Ondrey Form 3 Mirati Therapeutics / Aaron Ondrey ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Ondrey Aaron

(Last) (First) (Middle)

C/O MIRATI THERAPEUTICS, INC

3545 CRAY COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2023

3. Issuer Name and Ticker or Trading Symbol
Mirati Therapeutics, Inc. [ MRTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,028(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(2)	07/31/2032	Common Stock	11,933	65.79	D
Employee Stock Option (Right to Buy)	(3)	01/19/2033	Common Stock	11,844	45.66	D

Explanation of Responses:

1. This represents Restricted Stock Unit grants with vesting periods of 4 years that vest 25% annually from grant date, which were August 1, 2022 and January 20, 2023.

2. 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was August 1, 2022 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.

3. 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was January 20, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.

Remarks:

	/s/ John Moriarty, Attorney-in-Fact	09/12/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.